Wolters Kluwer Health (EURONEXT: WKL) announced on Wednesday that it has launched AI Article Summary on its Ovid platform, enabling researchers to quickly extract insights from peer-reviewed literature. Currently in Beta across selected LWW proprietary journals, the tool uses generative artificial intelligence to deliver concise, trustworthy summaries, streamlining information gathering for healthcare professionals, researchers and students.
AI Article Summary helps users identify key points from lengthy research papers, addressing the challenge posed by the growing volume of daily published studies. The feature supports rapid knowledge sharing among colleagues and allows clinicians and researchers to stay current with the latest evidence. Summaries are structured consistently across journals, providing practical, actionable information that aligns with clinical decision-making.
Designed with research workflows in mind, Ovid's AI summarisation highlights critical findings and methodological insights without requiring users to leave the platform. Specialized prompt engineering ensures clinically and scientifically relevant information is extracted efficiently and reliably.
Wolters Kluwer is a global provider of information, software solutions, and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance; and ESG. The group reported 2024 revenues of EUR5.9bn, serving customers in over 180 countries with operations in more than 40 nations and a workforce of approximately 21,600. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
Fusion Antibodies secures USD460,000 in follow-on contracts with US biotechnology client
INOVIO to begin rolling submission of BLA for INO-3107
ZYUS Life Sciences begins Phase 2a cancer pain trial with first patient enrolled
Curasight secures approval for phase 1 trial of uTREAT in glioblastoma patients
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
Calluna Pharma begins Phase 2 study of CAL101 in idiopathic pulmonary fibrosis
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
BioArctic and Novartis sign an option, collaboration and license agreement
Curasight's uTREAT clinical trial application approved in Europe
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Lighthouse Pharmaceuticals announces receipt of USD49.2m grant from NIA for LHP588 study
Innovent Biologics receives approval over squamous cell lung cancer study
Cambrex announces expansion of peptide manufacturing capabilities in Waltham, Massachusetts
Tyra Biosciences doses first child in dabogratinib Phase 2 achondroplasia clinical study